The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.
Yescarta is the First and Only Treatment in Nearly 30 Years to Demonstrate Superior Overall Survival for Patients with Relapsed/Refractory Large B-cell Lymphoma Versus Standard of Care as.
21.12.2023 - Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase .
– ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma –
– Four-Year Follow-up from.